(IN) with influenza A-(H2N2) virus, KS-2 was found to possess significant protective activities. Efficacy of the agent was evidenced by an increase in survivor number, a prolongation of mean survival time, an inhibition of the development of lung consolidation induced by the viral infection and a decrease in virus titer in lung tissues. Both PO and IP administrations of KS-2 protected mice against infection and significant antiviral activities were achieved not only by prophylactic but also chemotherapeutic administration.
No virocidal or virostatic activities of KS-2 to the influenza virus were found in vitro. The protective activities of KS-2 against influenza virus infection in mice are discussed in view of the immunopotentiation of the host animals.
Chemotherapy of viral infections including influenza and herpes viruses is a formidable task.
Antiviral agents without toxicity but exhibiting highly therapeutic value have been intensively searched in many laboratories for a long time. We have carried out in vivo screening for a protective substance against influenza diseases using a mouse model which acts through a potentiation of the defense mechanisms of the host animal rather than a direct inhibition of the viral growth. Three kinds of IF inducer, viz., a natural double-stranded RNA (S-dsRNA) extracted from the spores of Lentinus edodes='", dextran phosphate (DP-40) prepared by a chemical phosphorylation of dextran" and a glutarimide antibiotic (9-methylstreptimidone, 9-MS) isolated from a culture filtrate of Streptoinyces sp. S-885',", have been discovered during the screening program. These inducers are unique in their characteristics. For example, S-dsRNA accomplishes a high level of protection against influenza A/SW-15 virus infection in mice .2), whereas a potent IF inducer of a synthetic double-stranded RNA, polyriboinosinic-polyribocytidylic acid, is almost ineffective against such influenza A infection"'.
Both DP-40"' and 9-MS'' induce higher titers of IF in lung tissue, the site of influenza virus multiplication than in the serum. The protective effects and the stimulation of 1F production. however, are observed, only when these inducers are given IP or intravenously (IV) to mice''". THE 
JOURNAL OF ANTIBIOTICS
Recently, we observed IF production to be induced by both PO and 1P administrations of a new antitumor agent, KS-2, which was extracted from culture mycelia of Lentinus edodes as an immunopotentiator. KS-2 possesses a-mannose linked to a small peptide' with an estimated molecular weight of 6x10°-9.5x10'. When given either PO or IP, KS-2 suppressed the growth of various transplanted tumors in mice and rats through the potentiation of the host's function and not through direct inhibition of growth of the tumor cells. The acute LD;0 of the immunopotentiator is more than 12,500 mg/kg when administered PO to mice'. This fact may indicate the potential application of KS-2 in man. The purpose of this paper is to describe the IF-inducing capacity of this immunopotentiator and its protective activity against influenza virus infection in mice.
Materials and Methods
Drug preparation KS-2 used in this study was extracted from culture mycelia of Lentijurs edodes. Its characteristics and isolation procedure were reported previously'. The final product, a white amorphous lyophilized powder, was dissolved in sterile 0.01 M phosphate-buffered 0.15 M saline (PBS, pH 7.4) immediately before use and 0.5 ml of the solution containing an appropriate concentration was injected into mice. Virazole> (1-D-ribofuranosyI-1,2,4-triazole-3-car boxamide) was used as the positive control for an anti-influenza drug. Purified protein derivative (PPD), which was used as a stimulator of type 11 IF induction, was kindly supplied by Dr. SUGANUMA, Mitsui Pharmaceutical Co., Ltd., Mobara, Chiba, Japan.
Mice White DDI mice of both sexes weighing 18 -20 g were used throughout the study. They were obtained from the Central Farm of Tohoku University where care was taken to prevent infections with Sendai virus and Mycoplasma.
Cells
Monolayer cultures of the thymidine-kinaseless mutant strain of mouse fibroblasts, L-1D cells, were grown in Roux bottles in EAGLE'S minimal essential medium (MEM) supplemented with 10° bovine serum and used as the target cells for IF titration. Primary cultures of human embryonic lung (HEL) cells grown in MEM supplemented 10% calf serum were used to examine the host species specificity of the IF induced by KS-2.
Viruses
For the IF assay, the Indiana strain of vesicular stomatitis virus (VSV), propagated in the L-1 D cells and stored at -80°C, was used as a challenge virus. The 50 % tissue culture infectious dose (TCID.,,) of VSV was 107•°/ml in these cells. The mouse adapted Kumamoto strain of influenza A2 (H2N>) virus was used for the infection'). The virus was propagated once in the allantoic cavity of embryonated chicken eggs and the 48-hour allantoic fluid was used as the inoculum. The 50% egg infectious dose (EID>°) of the fluid was 109-'-/ml, which corresponded to 10'-0 LD.,,, in mice inoculated IN according to our standard inhalation procedure1" IF The tube culture assay technique (RYTEL and BALAY"') with a minor modification was employed for the measurement of serum IF obtained from KS-2 treated mice. Briefly, the L-ID cells were seeded 3 days before the test so that each tube contained 1.8 -2.0 x 10' cells. Serial 2-fold dilutions of serum specimens obtained from KS-2 treated mice were made in maintenance medium (MEM and 2°,o calf serum) and added to monolayer cultures of L-1D cells. After 18-24 hours of stationary incubation at 37°C, the medium was aspirated and the cultures washed once with HANKS' balanced salt solution. A dose of 100 TCID;o of VSV was inoculated into each tube. After 20-24 hours of stationary incubation at 37°C, the cytopathic effect (CPE) in the treated tubes was compared with the controls. The IF titers were determined as the reciprocals of the highest dilution of the specimens that produced 50% The lungs of infected mice were disrupted by a polytron homogenizer (Swiss Kinematica Co., Ltd., Switzerland) and made up to a 10°0 suspension with nutrient broth.
The suspension was then clarified by centrifugation at 1,580 t' for 10 minutes. The supernatants were serially diluted 10-fold with broth and 0.2 ml of each dilution was inoculated into the allantoic cavities of 3 embryonated eggs.
After incubation for 72 hours at 36 C, the allantoic fluid was removed from each egg and tested for its hemagglutinin titration titer by SAEK's pattern method.
The EID,,) per organ was calculated by the method of REED and MUENCH.
Calculation of lung consolidation score
Before autopsy, the lungs of the infected mice were irrigated by intracardiac injection of 0.01 M phosphate buffer (pH 7.2) to remove trace amounts of red blood cells. The amount of consolidation was scored macroscopically according to the method of HORSFALL"'.
Evaluation of antiviral activity in mice
The drug dissolved in PBS was administered PO or IP on a milligram per kilogram basis according to the schedule. The criteria for anti-influenza activity were based on: (1) An increase in the mean survival time of mice succumbing to infection during the 30-day observation period; (2) an increase in the number of survivors on day 30; (3) a decrease in the virus titer in lung tissues; (4) an inhibition of the lung consolidation induced by the viral infection. The results obtained were evaluated statistically by the means of the STUDENT'S t (average of survival days) and chi-square (survival %) tests. If the P value obtained in each test was below 0.05, the drug dose was considered to have had a significant antiviral activity.
In vitro antiviral test
In the CPE inhibition test, L-1D cells were grown in test tubes, and KS-2 of appropriate concentrations was added to the cultures at the time of VSV infection in a dose of 100 TCD,o. Uninfected control tubes were always included to determine toxicity of each concentration of KS-2. After incubation at 37°C, these cultures were examined daily for virus induced CPE. Antiviral activity of the compound was determined when control cultures (infected, without KS-2) showed complete CPE. In the virus yieldreduction test, embryonated eggs were infected with influenza A2/Kumamoto (HCNs) virus at a dose of 10 EIDso, and then 0.2 ml per egg of broth with or without KS-2 was injected to the allantoic cavity.
Forty eight hours after incubation at 37 C. these eggs were harvested at 4'C for 18 hours. And obtained VOL. XXXII NO. 12 THE JOURNAL OF ANTIBIOTICS allantoic fluids were assayed for their virus titers by EIDao method. hibitor is host-species specific ( Table   2 ). The antiviral activity was readily degraded by trypsin treatment. The activity was also inactivated significantly by both acid dialysis and heat treatment (Table 3) hours after IV injection of PPD at a dose of 0.5 mg/kg was used as a standard type II IF. d) IF samples containing a 500 mcg/ml concentration of trypsin were incubated at 37°C for 2 hours. e) Resistance to heat was determined by exposing sera to 56'C for 1 hour at neutral pH. f) Dialysis against pH 2.0 buffer was conducted at 4-C for 20 hours and was followed by redialysis against PBS (pH 7.2) for 20 hours. Table 5. THE  JOURNAL  OF ANTIBIOTICS  DEC.  1979 challenged with 20 LD.,o of influenza virus. The first group of 10 mice was given two IP doses of 141 mg of KS-2/kg prophylactically, 48 and 24 hours before virus infection. Another two groups of 10 mice were also treated chemotherapeutically with the same amount of IP administered KS-2 at different time intervals. Namely, the treatments were initiated 24 or 48 hours after the viral challenge, respectively, and continued once daily for 5 successive days. The last group of 40 mice was given PBS and served as the control. These results are shown in Table 6 , in which all of the control mice died within I I days of virus infection (mean survival days: 9.6), and the group treated in the prophylactic manner gave a 50% survival rate (mean survival days: >20.3). The group treated chemotherapeutically also survived more than 30 days postinfection at the rate of 60 (the group given treatment 24 hours after infection: mean survival days: >22.0) and 30% (the group given treatments 48 hours after infection; mean survival days: > 16.2), respectively. Both increases in survival rate and mean survival days of KS-2 treated mice were statistically significant. Therefore the protective effect of KS-2 was demonstrated by chemotherapeutic as well as prophylactic administration.
Results

11--inducing Activity of KS-2 in Mice
Effect of KS-2 on the Development of Lung Consolidations in Influenza Infected Mice
Sixty mice were infected IN with 10 LD50 of influenza virus. One half of these mice was given :a single administration of 200 mg/kg of KS-2 IP, and the other half served as the control. KS-2 was administered 24 hours after virus infection and once daily for 4 consecutive days. Ten mice from both groups were sacrificed at 2-day intervals from day 3 to day 7 for the calculation of lung consolidation scores. As shown in Table 7 , although lung lesions were found in all the control mice on day 5 (mean consolidation score: 1.7), almost no lesions were found in the treated group on the same day (mean score: 0.5). On day 7 the lungs of the control group showed almost complete consolidation (mean score: 3.9). In contrast the consolidation score of the treated group on day 7 (mean score: 1.8) was comparable to that of the control on day 5. The difference between the control and treated group was significant (P 0.005) when the 5-and 7-day results were compared. The result of the consolidation score showed a delay of about 2 days in the treated group. Table 8 
Discussion
Several natural and synthetic immunopotentiators, including IF inducers such as polyriboinosinicpolyribocytidylic acid') and pyran''', and many immunotherapeutic agents for cancer prepared frorr bacterial cells such as Mycobacterium tuberculosis strain BCG1G) and Corynebacterium parvum1 ) inhibit viral infections in vivo. Although the mechanisms of the antiviral action of these immunopotentiators have not been rigorously defined, it is usually understood that the protective effects of IF inducer appear to be due to the IF induced","'.
However, the protective action of the immunotherapeutic agents remains to be clarified although the activated reticuloendothelial and cellular immunity systerr might be involved",").
Recently KIRCHNER et al.12 "_3) reported that killed Corynebacterium parvum induced an immune IF in vivo as well as in vitro. More recently we observed the 1F-inducing activity by some immunotherapeutic agents24-26) such as a whole cell preparation of an avirulent Streptococcus pyrogenes (OK-432)2.', an antihelminthic drug of thiazole derivation (levamisole)28' and a high molecular weight /3-1,3 glucan (lentinan) extracted from the fruitbody of Lentinus edodes211.
In the present paper, we examined KS-2 for its IF-inducing capability in experimental animals and for its protective activity against influenza in mice. The results showed that an immune IF was produced by IP or PO administration of KS-2 in mice (Tables I '-4, Fig. 1 ) and KS-2 exhibited a significant activity against the infections of lethal doses of influenza A2 (H,N_) virus in mice when given either Note: One ml of 106 TCID.,o of VSV/ml or the same amount of 10' EID5o of influenza A2 (H2N2) virus was mixed with 1 ml of broth containing 2-4 mg/ml of KS-2, formalin and broth alone, respectively. Five hours after incubation at 37°C, each mixture was titrated for the residual activity of the viruses. PO or IP (Table 5 , Fig. 2 ). Significant protection (30°0.60% of survival rates) was achieved by therapeutic as well as prophylactic treatment (50% survival rate), whereas 100% mortality was observed in the control group (Table 6 ). In addition, the marked antiviral activities of KS-2 were seen by decreased titers of the virus in lung tissues (Table 8 ) and reduced scores of lung consolidations (Table 7) in infected mice. The results showed that KS-2 itself had no direct action on virus particles and virus infected cells in vitro (Table 9 ). Thus KS-2 possesses significant antiviral activity against influenza disease in mice through a potentiation of the host's defense functions and the antiviral action of KS-2 is exhibited through its IF-inducing activity. However, further investigation along this line is required for a more detailed elucidation of the mechanism of action. In contrast to the viral inhibitory activity, several immunopotentiators enhance a host's tumor suppressive capacity' 27-), ), and the antitumor mechanism has been demonstrated to be engendered by tumoricidal activated macrophages"',"". Furthermore SCHULTZ_ et al." reported that macrophages became tumoricidal when incubated in vitro with highly purified IF. Our preliminary data indicated that macrophages obtained from mice treated with OK-432, lentinan, levamisole or KS-2 exhibited tumoricidal activity. Taking all these observations together, the antiviral and antitumor activities of the immunopotentiators may be explained through the function of IF. More detailed analysis on the relationships between the IF-inducing capability and the antitumor or antiviral activity of the immunopotentiators should be carried out.
